Reportedly, the European Medicines Agency has recommended the use of CAR-T therapy to treat multiple myeloma by Johnson & Johnson (JNJ) and its partner Legend Biotech Corp. (LEGN) nearly a month after the treatment was cleared in the United States. The drug now needs the approval of the European Commission, as it holds the final word on market access. The drug was initially tested in China and later in the United States and Japan, however, the drugs that have only been tested in China have faced increased scrutiny by the U.S. Food and Drug Administration.
Carvykti is a part of drugs known as CAR-T therapies (chimeric antigen receptor T-cell therapies), which involves extracting disease-fighting T-cells from a patient, re-engineering them to attack cancer, and then infusing them back into the body. Legend Biotech Corp and J&J plan to sell the drug in Greater China at 70-30 profit and a 50-50 profit in all other countries.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.